ANKS1A

Across TCGA pan-cancer cohorts, ANKS1A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANKS1A data layer compared with 24 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ANKS1A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ANKS1A expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where ANKS1A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.919	0.363	<.001	33	view →
LSCC	OS	Median	All	1.000	0.938	.013	26	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	21	view →
HNSC	DFS	Tertile	II,III,IV	0.986	0.863	.010	14	view →
OV	DFS	Median	All	0.918	0.565	.035	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ANKS1A–CCRCC (DFS)

Open the CCRCC breakdown →